Dehydration News and Research

Latest Dehydration News and Research

OraSure to introduce QuickFlu test for detection of type A and type B influenza

OraSure Technologies, announced today the impending launch of the OraSure QuickFlu Rapid Flu A+B Test, a U.S. Food and Drug and Administration approved in vitro rapid qualitative test for the detection of influenza type A and type B, including H1N1 viral infections.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

10 Jan 2011

Tips for surviving a bout with 'stomach flu'

A post-holiday crush of patients are crowding into area physician offices and hospital emergency rooms as individuals of all ages suddenly find themselves laid low by a highly contagious and quick-striking virus.

10 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

According to the American Academy of Pediatrics, sweetened drinks are the primary source of added sugar in the daily diet of children. Each 12-ounce serving of a carbonated, sweetened soft drink contains the equivalent of 10 teaspoons of sugar and 150 calories. A child who consumes one can of regular soda needs to walk 45 minutes just to burn it off.

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Tips to prevent a hangover

Dr. Andrew Yacht, director of the division of general medicine and vice chair of medicine for education at Maimonides Medical Center in New York City said, “Alcohol clearly causes hangovers, but why it causes hangovers isn’t very well understood…Part of the suspected cause is dehydration and an electrolyte and hormonal imbalance. Some of the symptoms may be caused by low blood sugar. Or, it may be that the direct toxic effects of alcohol are causing the symptoms.”

2 Jan 2011

Loyola University offers tips to avoid the misery of New Year's hangover

Exercise and B vitamins can help cure a hangover, but coffee won't help. These are among the tips that Loyola University Health System family physician Dr. Aaron Michelfelder offers to avoid the misery of a New Year's hangover.

30 Dec 2010

Hangover tips for the festive season!

A bad hangover usually comes with a variety of symptoms like headaches, fatigue, upset stomach, sweating, nausea, bad taste in the mouth excessive thirst, sensitivity to light etc. This is mainly due to the diuretic effects of alcohol that leaves one dehydrated.

28 Dec 2010

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products: Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial

24 Dec 2010

Tips to find if a senior relative needs immediate medical attention

You're in from out of town and stop by to see Great Aunt Edna and Great Uncle Albert for the first time in a few years. But you become worried when you observe that the busy, meticulous couple of your youth is gone, replaced by a disheveled woman who won't get out of bed and a belligerent man who doesn't recognize you and thinks it is 1959.

21 Dec 2010

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

Exertional heat-related injuries also occur during everyday activities

A new study conducted by researchers at the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital examined exertional heat-related injuries that were treated in emergency departments between 1997 and 2006. Exertional heat-related injuries are injuries that occur as a result of exercise or physical activity during warm or hot temperatures.

8 Dec 2010

HDAC inhibitors may be used to fight against skin cancers

In a study published in the journal Developmental Cell, Sarah Millar PhD, professor of Dermatology and Cell & Developmental Biology at the University of Pennsylvania School of Medicine, and colleagues demonstrate that a pair of enzymes called HDACs are critical to the proper formation of mammalian skin.

7 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

Dehydration News and Research

Latest Dehydration News and Research

OraSure to introduce QuickFlu test for detection of type A and type B influenza

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

Shionogi brings KAPVAY ADHD drug to the U.S market

Tips for surviving a bout with 'stomach flu'

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

GLUMETZA tablets are now available to wholesalers and physicians

Tips to prevent a hangover

Loyola University offers tips to avoid the misery of New Year's hangover

Hangover tips for the festive season!

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

Tips to find if a senior relative needs immediate medical attention

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Exertional heat-related injuries also occur during everyday activities

HDAC inhibitors may be used to fight against skin cancers

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Dehydration News and Research

Latest Dehydration News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in